tbuckley/cabot-search huggingface dataset:
Sleep Disruption in Chronic Rhinosinusitis: Risk Factors Predictive of Worse Sleep Quality
Authors: Jessica W. Hui, Ferry Gunawan, Jason Ong, Helen J. Burgess, Shahram Sarrafi, James J. Herdegen, Christopher D. Codispoti, Mary C. Tobin, Robert P. Schleimer, Pete S. Batra, Phillip S. LoSavio, Ali Keshavarzian, Mahboobeh Mahdavinia
Journal: Journal of Allergy and Clinical Immunology (2017)
Examining the relationship between social cognitive processing and depressive symptoms in long-term breast cancer survivors and their partners.
Authors: Andrea A Cohee, Victoria Champion
Journal: Journal of Clinical Oncology (2016)

191 Background: Breast cancer survivors (BCS) and their partners frequently report distress, including depressive symptoms after diagnosis and treatment for breast cancer. The Social Cognitive Processing Theory (SCPT) has been useful in identifying predictors of both BCS and partner distress, although most studies have occurred early in survivorship. Relationships between SCPT variables and depressive symptoms in long-term BCS and their partners have not been well explored. The purpose of this study is to test relationships between SCPT variables and depressive symptoms in long-term BCS and their partners. Methods: In a large cross-sectional study, BCS (N = 222), who were 3-8 years from diagnosis, and their partners completed a survey assessing demographic characteristics, social constraints, cognitive processing (intrusive thoughts and cognitive avoidance), and depressive symptoms. Mediation analyses were conducted for survivors and partners separately to determine if cognitive processing would mediate the relationship between social constraints and depressive symptoms. Results: Cognitive processing mediated the relationship between social constraints and depressive symptoms both for BCS [F(5,209) = 16.373, R 2 = .281, p &lt; .001] and partners [F(4, 216) = 8.281, R 2 = .133, p &lt; .001), controlling for age, education, and survivors’ time since diagnosis. Although included in the model, demographic variables did not significantly predict depressive symptoms. Conclusions: Relationships in the SCPT were confirmed; cognitive processing mediated the relationship between social constraints and depressive symptoms for both long-term BCS and their partners. Results expand the utility of the SCPT in long-term survivors and their partners by supporting its use in intervention design.
Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
Authors: G. Scagliotti, T.M. Kim, L. Crinò, G. Liu, C. Gridelli, S. Novello, K. Kiura, A. Bearz, O. Gautschi, E. Felip, M. Nishio, D.R. Spigel, T.S.K. Mok, P. Urban, S. Deudon, C. Zheng, A.T. Shaw
Journal: Annals of Oncology (2016)
Gene Expression Profiles of CD34+ Cells from PBSC Grafts Predict for Development of t-MDS Following Autologous Transplantation for HL/NHL.
Authors: Liang Li, Xiwei Wu, David Smith, Jerald P. Radich, Lue Ping Zhao, Liton Francisco, Asako Komiya, Holly Damasco, Stephen J. Forman, Smita Bhatia, Ravi Bhatia
Journal: Blood (2007)
Perlecan and vascular endothelial growth factor-encoding DNA-loaded chitosan scaffolds promote angiogenesis and wound healing
Authors: Megan S. Lord, April L. Ellis, Brooke L. Farrugia, John M. Whitelock, Hernan Grenett, Chuanyu Li, Robert L. O'Grady, Arthur A. DeCarlo
Journal: Journal of Controlled Release (2017)
416P Typical morphological features revealed unfavorable survival benefits in high-grade neuroendocrine carcinomas
Authors: H.-R. Zhai, J.-T. Zhang, L.-X. Yan, C. Zhang, J. Su, S. Dong, Q. Nie, R.-Q. Liao, B.-Y. Jiang, X.-N. Yang, Y.-L. Wu, W.-Z. Zhong
Journal: Annals of Oncology (2016)
Microdeletions at Apparently Balanced Translocation Breakpoints Are Biomarkers for Heightened Genomic Instability in Patients with Non-MLL Acute Myeloid Leukemia
Authors: Roger A. Schultz, Theresa C. Brown, Lynda J. Campbell, Meaghan Wall, Jacqueline Schoumans, Jin-Yeong Han, Urvashi Surti, Eric Crawford, S. Dwanna Stewart, Raymond R. Tubbs, James R. Cook, Aaron M. Gruver, Asad Dean, Haluk Tezcan, Aubry Furrow, Lisa G. Shaffer, Blake C. Ballif
Journal: Blood (2011)
High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping
Authors: F. Rodriguez-Frias, L. Nieto-Aponte, J. Gregori, D. Garcia-Cehic, R. Casillas, D. Tabernero, M. Homs, M. Blasi, M. Vila, Q. Chen, V. Vargas, Ll. Castells, Ll. Viladomiu, J. Genesca, B. Minguez, S. Augustin, M. Riveiro-Barciela, J. Carbonell, C. Perales, M.E. Soria, M. Asensio, M. Llorens, L. Ordeig, C. Godoy, M. Buti, R. Esteban, T. Pumarola, J.I. Esteban, J. Quer
Journal: Clinical Microbiology and Infection (2017)
Long lasting survival (LLS) after removal of primary tumor (PT) in metastatic breast cancer (MBC). Impact of age on outcome
Authors: J.A. Perez Fidalgo, A. Caballero, J.M. Cejalvo, O. Burgues, C. Hernando, P. Tolosa, A. Iranzo, B. Bermejo, J.B. Ramirez Sabio, A. Magro, A. Lluch-Hernandez
Journal: Annals of Oncology (2016)
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
Authors: Clara K Chow, Jay Thakkar, Alex Bennett, Graham Hillis, Michael Burke, Tim Usherwood, Kha Vo, Kris Rogers, Emily Atkins, Ruth Webster, Michael Chou, Hakim-Moulay Dehbi, Abdul Salam, Anushka Patel, Bruce Neal, David Peiris, Henry Krum, John Chalmers, Mark Nelson, Christopher M Reid, Mark Woodward, Sarah Hilmer, Simon Thom, Anthony Rodgers
Journal: The Lancet (2017)
349P A retrospective multicenter survey of hepatitis B virus infection (HBV) screening and HBV-DNA monitoring in patients receiving hematopoietic stem cell transplantation and rituximab-based chemotherapy
Authors: T. Nakashima, Y. Ohashi, S. Oki, R. Saito, K. Koido, C. Ogawa, N. Sato, K. Seto, Y. Negishi, N. Kondo, M. Kikuchi, A. Yokoyama, H. Ueno, M. Koinuma, Y. Yachi, H. Terakado
Journal: Annals of Oncology (2016)
Biomarkers of radiation exposure in children with neuroblastoma treated with <sup>131</sup>I-mIBG.
Authors: Erin E Karski, Katherine K. Matthay, M. Shelly Allen, Matthew Coleman, Ayona Kohlgruber, Daphne A. Haas-Kogan, Aleksandra E Olow, Steven G. DuBois
Journal: Journal of Clinical Oncology (2013)

10060 Background: Neuroblastoma (NB) is the most common solid extra-cranial tumor of childhood. 131 I-mIBG is a targeted radiopharmaceutical for patients with advanced NB and is one of the most active agents in this treatment resistant population. To date, no clinically relevant biomarkers of response or toxicity have been reported in patients treated with 131 I-mIBG. Methods: Patients with relapsed or refractory NB who received 131 I-mIBG at UCSF were eligible to participate in this prospective correlative study. Blood samples were obtained at baseline and 72 hours after 131 I-mIBG infusion. We quantified a panel of biomarkers shown to be effected in patients receiving other forms of radiation, including: serum amylase; plasma Flt-3 ligand; plasma monocyte colony stimulating factor (MCSF); and CDKN1A mRNA in mononuclear cells. Extent of modulation of each marker was evaluated using paired t-tests at hour 0 and 72. We assessed potential differential modulation between groups based on response (PR/CR vs SD/PD), toxicity (grade 3 non-hematologic toxicity; grade 4 neutropenia or thrombocytopenia) or administration of combination therapy ( 131 I-mIBG alone vs in combination with vincristine/irinotecan or vorinostat) using unpaired t-tests. Results: 26 patients (21 male; median age 7 years) participated and received a median 131 I-mIBG dose of 18 mCi/kg. 16 patients received 131 I-mIBG in combination. We observed robust modulation of amylase (median fold increase from baseline 3.1; p &lt;0.0001), Flt-3 ligand (median fold increase from baseline 3.6; p=0.0005), and CDKN1A mRNA (median fold decrease from baseline 4.3, p=0.0002). No differences were noted in MCSF (p=0.80). Patients receiving combination 131 I-mIBG had more robust modulation of Flt-3 ligand (mean difference 296 pg/mL; p=0.02) compared to single agent 131 I-mIBG. No correlations with clinical response or toxicity were found. Conclusions: Amylase, Flt-3 ligand, and CDKN1A mRNA all show robust modulation after 131 I-mIBG treatment. Patients receiving 131 I-mIBG in combination demonstrated the largest changes in plasma Flt-3 ligand. In this initial analysis, no associations were found between response or toxicity and the proposed biomarkers.
331P Synergistic effects of ferula gummosa and radiotherapy to induce cytotoxicity and apoptosis in the hela cell line
Authors: A. Fani-Pakdel, S.H. Forouzmand, S.H. Mousavi, V. Vazifedan, M. Nourbakhsh, S. Soleymanifard, J. Chamani
Journal: Annals of Oncology (2016)
CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Authors: R. Baird, J. Garcia-Corbacho, N. Ramenatte, A. Jonson, S. Ahmad, D.-M. Smith, W. Qian, S. Kumar, C. Linossi, T. Matys, M. Graves, D. Jodrell, C. Caldas, S. Pacey, G. Whitfield, A. Chalmers, R. Jena, S. Price, S. Jefferies, C. Watts
Journal: Annals of Oncology (2016)
Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients
Authors: K Martin Kortuem, Esteban Braggio, Pieter Sonneveld, Laura Ann Bruins, Santiago Barrio, Davine Hofste op Bruinink, Mark vanDuin, Elias Karl Mai, Nur Hanafiah, Hartmut Goldschmidt, Sanchin Pathangey, Yanira Ruiz Heredia, Inmaculada Rapado, Beatriz Sanchez-Vega, Stefan Knop, Leo Rasche, Christian Langer, Miriam Kull, Lars Bullinger, Monika Engelhardt, Joaquin Martinez-Lopez, Hermann Einsele, Marc S. Raab, A. Keith Stewart
Journal: Blood (2015)
Fludarabine, Idarubicin and High Dose Cytarabine (FLAG-IDA) Followed by Allogeneic Transplantation: A Successful Strategy for Remission Re-Induction in High Risk Pediatric Patients with Relapsed, Refractory and Secondary Acute Leukemias.
Authors: Melissa A. Gabriel, Tracey A. O’Brien, Heather Tapp, Barbara Chamberlain, Glenn M. Marshall, Richard J. Cohn, Cecelia Oswald, Susan J. Russell
Journal: Blood (2006)
Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers.
Authors: Vit Prochazka, Martin Novák, Zuzana Pikalova, Tomas Papajik, Karel Indrak, Vladimir Divoky
Journal: Blood (2012)
Seminoma and sarcoid: A confusing collision.
Authors: Claire Brady, Richard Martin Bambury, MinYuen Teo, Alamani El-Gammal, Julie McCarthy, Martin O'Driscoll, Marcus Kennedy, Terry O'Connor, Seamus O'Reilly, Derek Gerard Power
Journal: Journal of Clinical Oncology (2012)

339 Background: In patients with active or prior malignancy, the presence of mediastinal lymphadenopathy is often assumed to indicate metastases. However, sarcoidosis can imitate malignancy on CT and PET imaging. The incidence of sarcoidosis or “sarcoid-like reaction” in cancer patients (especially testicular germ cell tumor patients) appears to be higher than in the general population. Methods: We report a series of 4 testicular cancer patients with mediastinal adenopathy mimicking metastatic disease. Subsequent investigations and follow-up revealed sarcoid-like reaction without active malignancy. Results: A 25 year old man presented with a neck swelling and was found to have left cervical adenopathy, mediastinal adenopathy and a right testicular mass. Biopsy of the cervical nodes revealed a mixed seminoma and non-seminomatous germ cell tumour. After 4 cycles of chemotherapy PET/CT revealed persistent hypermetabolic mediastinal adenopathy. Transbronchial needle aspirate (TBNA) revealed non-caseating granulomas (NCGs). After right orchiectomy and retroperitoneal lymph node dissection he remains in complete remission. A 26 year old man presented with scrotal swelling and investigations revealed bilateral testicular seminoma. CT revealed mediastinal adenopathy. TBNA revealed NCGs and he remains disease free after orchiectomy. A 42 year old man presented with right sided scrotal swelling. CT revealed mediastinal adenopathy. TBNA revealed NCGs. He was treated successfully with orchiectomy and chemotherapy for stage 1 seminoma. A 20 yr old man had mediastinal adenopathy on a surveillance CT 5 years after high dose chemotherapy and stem cell transplant for platinum-refractory seminoma. TBNA revealed NCGs and the adenopathy resolved with oral prednisone therapy. Conclusions: Sarcoid-like reaction in cancer patients may be due to an immunologic hypersensitivity to tumor-associated antigens. Although the precise pathogenesis is unknown, the clinical relevance of this phenomenon is clear. There is a need for histologic confirmation of suspected metastatic mediastinal adenopathy in patients with testicular cancer. We are collecting more cases in other malignancies and will present an update.
A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.
Authors: Kenneth B. Miller, Nelson J. Chao, Hans A. Messner, Steven C. Goldstein, Vijay Reddy, William Vaughan, Steven Devine, Scott D. Rowley, Ned Waller, Marcel Devetten, Gary J. Schiller
Journal: Blood (2006)
Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstrom’s Macroglobulinemia
Authors: Alessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, Marta Battista, Sara Miqueleiz, Francesca Ricci, Michele Nichelatti, Francesco Zaja, Pier Luigi Zinzani, Vittorio Meneghini, Pietro Pioltelli, Mario Lazzarino, Umberto Vitolo, Enrica Morra
Journal: Blood (2008)
Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation
Authors: Jesus Duque-Afonso, Antje Prasse, Ralph Wäsch, Hartmut Bertz, Jurgen Finke, Reinhard E Marks
Journal: Blood (2010)
Impact of sleep disturbance in myelodysplastic syndromes (MDS).
Authors: Roxanne M. Solis, Angel Cronin, Corey D. Watts, David P. Steensma, Richard M. Stone, Daniel J. DeAngelo, Robert L. Owens, Martha Wadleigh, Gregory Alan Abel
Journal: Journal of Clinical Oncology (2015)

99 Background: The fatigue of MDS is typically attributed to anemia and inflammatory cytokines expressed by hematopoietic cells. In contrast, the burden and impact of sleep disturbance in MDS has not been well-described. Methods: Starting in January 2006, patients with MDS seen at least twice at the Dana-Farber Cancer Institute (DFCI) were enrolled in a clinical database and underwent baseline administration of the EORTC QLQ-C30. This measure includes a question about sleep disturbance (“have you had trouble sleeping”) as well as a three-item fatigue assessment. For this analysis, we first determined if there were differences in fatigue assessment score by self-reported sleep disturbance, hemoglobin (Hb) and other clinical characteristics (age, gender, cytogenetic category, and blasts) using ANOVA. Next, a multivariable logistic regression model was created to determine the independent contribution of each factor to fatigue score above or below the sample median. Results: 251 patients had complete clinical and QLQ-C30 data. Median age was 68 years; 68% were men. The IPSS distribution was 18% Low, 38% Int-1, 29% Int-2 and 15% High. Median fatigue score was 33 out of 100 (IQR 33-56; reference value for similar-aged cancer patients is 33 with IQR 11-56). The majority (53%) reported trouble sleeping, which was strongly associated with increased fatigue (p&lt;0.001). Among clinical factors, only lower Hb was also associated with fatigue (p&lt;0.001). Sleep disturbance did not vary with IPSS category (p=0.40), and was not strongly correlated with Hb (ρ= 0.10). On multivariable analysis adjusting for age, gender, cytogenetics and blasts, Hb &lt; 10 g/dL and the two highest levels of sleep disturbance independently predicted fatigue score above the median (p=0.003). Conclusions: Poor sleep is prevalent among patients with MDS, and is an independent predictor of fatigue when controlling for Hb. These data suggest that in addition to anemia, sleep disturbance should be addressed to relieve MDS-related fatigue. [Table: see text]
Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib
Authors: V. Neiman, D. Keizman, D. Sarid, J.-L. Lee, A. Sella, M. Gottfried, H. Hammers, M. Eisenberger, M. Carducci, V. Sinibaldi, E. Rosenbaum, A. Peer, A. Neumann, W. Mermershtain, K.R. Rouvinov, R. Berger, I. Yildiz
Journal: Annals of Oncology (2016)
IMST-16. TRANSLATABLE RNA NANOPARTICLES SUPPLANT DENDRITIC CELL VACCINES IN CELLULAR IMMUNOTHERAPY
Authors: Elias Sayour, Gabriel De Leon, Christina Pham, Adam Grippin, Catherine Flores, Duane Mitchell
Journal: Neuro-Oncology (2016)

In a pilot study, dendritic cell (DC) vaccines targeting glioblastoma (GBM) were shown to engender long-term survival outcomes (Mitchell et al. Nature, 2015). While these approaches have shown considerable promise, the advancement of cellular therapeutics through the commercialization pipeline has been encumbered by significant cost, complexity and time to generation. To circumvent the challenges associated with autologous cellular therapeutics, we developed a novel treatment platform, which leverages the use of commercially available and clinically translatable nanoparticles (NPs) that can be combined with tumor-derived RNA to systemically activate peripheral immunity against GBM antigens. To overcome the limitations of poorly immunogenic local vaccination strategies, we assessed if intravenous delivery of tumor-derived RNA encapsulated in lipophilic NPs could systemically activate antigen presenting cells (APCs) for induction of therapeutic anti-tumor immunity in pre-clinical murine GBM models. We identified a clinically translatable NP formulation for the delivery of RNA to APCs that induces in vivo gene expression and preserves RNA stability over time. When administered intravenously, RNA-NPs lead to systemic activation of host APCs in reticuloendothelial organs triggering precipitous upregulation of activation markers (MHCII, CD40, and CD86) and chemokine receptors (i.e. CCR7) on CD11c+ cells. We demonstrated that both model-antigen encoding RNA and physiologically-relevant tumor-derived RNA, when encapsulated in NPs, could expand potent anti-tumor T-cell immunity. T-cell immunity elicited by RNA-NPs was superior to peptide vaccines formulated in complete Freund’s adjuvant. We enhanced the immunogenicity of this platform by simply combining mRNAs encoding for immunomodulatory molecules (i.e. HCV PAMPs, GM-CSF). In a pre-clinical cellular immunotherapy model for invasive malignant glioma, RNA NPs were shown to supersede DCs in mediating anti-tumor activity. Since RNA-NPs bypass cost/complexity of cellular therapeutics, are amenable to central distribution, and can be made within days of tumor-resection, these formulations supplant DCs providing near-immediate immune induction against GBM.
Abstract B05: Repurposing FDA-approved drugs for anti-metastatic therapy: Results of an integrated genome wide screen for metastasis modifiers
Authors: Anjali Shukla, Kent W. Hunter
Journal: Cancer Research (2016)

Abstract Metastasis remains the primary cause of patient morbidity and mortality in solid tumors. Recent advances in genomic technologies have provided major insights into the etiology of tumors. However, significantly less is known about factors that contribute to metastasis. Here we report the results of a genome-wide integrated genetic, transcriptional, and epigenetic analysis in a mouse mammary tumor model to identify factors associated with tumor progression. This strategy identified a prognostic transcription signature and several upstream transcriptional regulators for metastatic disease. Interestingly, this analysis also identified novel or other FDA-approved drugs as potentially useful for anti-metastatic therapy. As predicted by this screen, administration of antidiabetic thiazolidones Rosiglitazone and Pioglitazone suppressed metastasis in an orthotopic breast cancer mouse model. Similarly, ciprofloxacin, an antibiotic, also decreased breast cancer metastasis. This strategy is thus not only of prognostic value but also presents the opportunity to rapidly repurpose drugs with proven safety and efficacy profiles for control and treatment of advanced neoplastic disease. Citation Format: Anjali Shukla, Kent W. Hunter. Repurposing FDA-approved drugs for anti-metastatic therapy: Results of an integrated genome wide screen for metastasis modifiers. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B05.
Mir-16 and 21 Deregulation Are Linked to Anti-Apoptotic Bcl-2 Gene Expression in Polycythemia Vera
Authors: Natalia de Souza Nunes, Raquel Tognon-Ribeiro, Livia G Moura, Simone Kashima, Dimas T Covas, Elizabeth xisto Souto, Maria Aparecida Zanichelli, Belinda Pinto Simoes, Ana Maria de Souza, Fabiola Attie de Castro
Journal: Blood (2012)
RTHP-05. INTRAOPERATIVE RADIOTHERAPY (IORT) USING LOW-ENERGY X-RAYS IN A COHORT OF PREDOMINANTLY INCOMPLETELY RESECTED NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (INTRAGO TRIAL)
Authors: Frank Anton Giordano, Stefanie Brehmer, Bettina Mürle, Grit Welzel, Elena Sperk, Anke Keller, Yasser Abo-Madyan, Sven Clausen, Frank Schneider, Carsten Herskind, Marcel Seiz-Rosenhagen, Christoph Groden, Peter Schmiedek, Martin Glas, Daniel Hänggi, Kevin Petrecca, Frederik Wenz
Journal: Neuro-Oncology (2016)

Local recurrence remains the predominant pattern of failure in glioblastoma multiforme (GBM), indicating that residual clonogenic tumor cells may need to be targeted by more intensive therapy of the tumor cavity. We performed a phase I/II trial (NCT02104882) to evaluate safety and tolerability of intraoperative radiotherapy (IORT) with 20-40 Gy of low-energy photons (50 kV) in addition to standard radiochemotherapy. The primary endpoint was occurrence of dose-limiting toxicities (DLT) within 3 months after IORT (wound healing deficits, cerebral bleeding/ischemia, brain necrosis and early termination of radiochemotherapy). Secondary endpoints were progression-free survival (PFS), local PFS (≤ 1cm to the cavity) and overall survival (OS). Fourteen patients with histologically confirmed IDH1wt GBM were included (median FU 12.4 months), 12 underwent incomplete resection, 9 had unmethylated MGMT promoters, 6 had unresectable satellites and 3 did not receive per-protocol treatment (PPT). No DLTs were observed at any dose level within the predefined time frame. The majority of grade 3-5 adverse events (21 of 25) were deemed related to chemotherapy or tumor progression. Radionecrosis was diagnosed in 3 patients which occurred after the predefined time frame. The median PFS was 10.3 months (95%CI: 5.2-15.4) in all and 11.4 months (95%CI: 9.8-13.0) in PPT patients. The median local PFS was 13.4 m (95%CI: 9.7-17.1) in all and 14.5 m (95%CI: 11.3-17.7) in PPT patients. The median OS was 14.5 m (95%CI: 9.8-19.2) for all and 16.5 m (95%CI: 11.5-21.5) for PPT patients. One distant response was observed without any change of treatment. IORT with low-energy photons in addition to standard therapy is safe and tolerable. Despite multiple poor prognostic factors, median and local PFS compare favourably to historic data (mPFS was 6.9 m in the EORTC/NCIC trial). The technique is now tested in a multinational randomized phase III trial (NCT02685605).